GET THE APP

Research of New Class C beta-Lactamase Inhibitor by Molecular Docking├ó┬?┬?s Method | Abstract
Scholars Research Library

Scholars Research Library

A-Z Journals

12013805565

Journal of Computational Methods in Molecular Design

Abstract

Research of New Class C beta-Lactamase Inhibitor by Molecular Docking├ó┬?┬?s Method

Author(s): Benhamoud Amina, Boufrah Mohsane, Mokrani El Hassen, Teniou Soumia, Bensegueni Abderrahmane

“In silico” molecular docking is a new theoretical approach in pharmaceutical chemistry that allows the prediction of the most favorable mode of interaction of a ligand within its receptor (therapeutic target) in a limited time and especially sometimes without having to synthesize these compounds. In our research, the molecular docking program, Surflex, has been used to develop in silico new inhibitors of class C Beta-Lactamase deactivating several beta-lactam antibiotics including Cephalosporins. By tri-substitution of a compound “GLB”, we were able to improve significantly its score from 4.51 to 7.91 by introducing a hydroxyl group at the C8b position, a carboxyl group at the C12 position and a benzene-3’-COOH ring at its C3 carbon. The application of the Lipinski rule allowed us to verify the bioavailability of the compound resulting from the tri-substitution that is considered as a new powerful theoretical inhibitor and selective for class C Beta-lactamase.